Clinical Trials
20
Active:2
Completed:12
Trial Phases
2 Phases
Phase 1:16
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Phase 1
16 (84.2%)Phase 3
3 (15.8%)Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06025214
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Phase 1
Active, not recruiting
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05982990
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Phase 1
Active, not recruiting
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05697003
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
Phase 3
Recruiting
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 451
- Registration Number
- NCT05664061
- Locations
- 🇬🇷
BECRO Ltd., Athens, Greece
A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions
Phase 1
- Conditions
- AsthmaBioequivalence
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05397834
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found